Cervical cancer is associated with Human Papillomavirus (HPV) and is the second most frequently occurring cancer among women and a major cause of cancer mortality worldwide in women. In this study, we used MY09/11 consensus real-time PCR to investigate the presence of HPV-DNA in the cervical smear samples. Secondly, we carried out genotyping analysis using real-time PCR with type-specific primers and probes were designed for the 12 high-risk HPVs (16, 18, 31, 33, 35, 39, 45, 52, 58, 59, 68 and 82). We detected 131 HR-HPV isolates in 106 cervical smear samples that were determined as HPV-DNA positive by consensus PCR. The distribution of
the most frequent high-risk HPV types as follows: HPV-16; 53 (40,5%), HPV-52; 17 (13%) and HPV-58; 14 (10,7%). In addition, according to retrospective data, diagnostic endometrial biopsy was performed in 44 patients (41.5%). The distribution of HPV genotypes in different pathological entities was also assessed. Current HPV vaccines are designed to protect against HPV-16 and HPV-18. More than half (51,9%) of the types identified in this study are except for HPV-16 and HPV-18. HPV-16 and HPV-18 detection rate may be less than this rate, when consider that the screening panel does not contain all HR-HPV types. For these reasons, we think that large-scale studies are needed to determination of the current type distribution in our country to the prediction of protective efficacy of HPV vaccines.
HPV, genotype, real-time PCR, cervical cancer